No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis

In conclusion, TDF is similar to entecavir in reducing HCC incidence among treatment-naïve CHB patients. Heterogeneous results of included studies may result from their disparity in follow-up length. Our findings should be treated with caution and need to be further confirmed.PMID:33658397 | DOI:10.18632/aging.202573

Source: Aging - March 4, 2021 Category: Biomedical Science Authors: Jie Yuan Yang Peng Fa-Bao Hao Ya-Qin Wang Chun-Rui Wang Guo-Chao Zhong Source Type: research